Skip to main content

approvalsWatch: Oncology 301015

US FDA Approvals

The US FDA has approved the alkylating agent trabectedin for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have previously been treated with an anthracycline-based regimen.

Talimogene laherparepvec
The first-in-class oncolytic virus therapy talimogene laherparepvec has been approved for adult melanoma patients with recurrent disease after initial surgery. The agent is administered by injection directly into unresectable cutaneous, subcutaneous and/or nodal lesions.

Following an approval extension, the anti–CTLA-4 agent ipilimumab can now be used as adjuvant therapy for stage III melanoma patients to reduce the risk of recurrence.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits